/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Travere Therapeutics Inc Share Price Today: Live Updates & Key Insights

Travere Therapeutics Inc share price today is $27.55, up -3.23%. The stock opened at $28 against the previous close of $28.47, with an intraday high of $28 and low of $26.97.

Travere Therapeutics Inc Share Price Chart

style
pb-0

Travere Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Travere Therapeutics Inc Share Price Performance

$27.55 -0.0323(-3.23%) TVTX at 13 Mar 2026 03:37 PM Biotechnology
Lowest Today 26.97
Highest Today 28
Today’s Open 28
Prev. Close 28.47
52 Week High 42.13
52 Week Low 12.91
Day’s Range: Low 26.97 High 28
52-Week Range: Low 12.91 High 42.13
1 day return -
1 Week return +1.24
1 month return -0.93
3 month return -20.65
6 month return +19.91
1 year return +44.17
3 year return +26.86
5 year return -3.26
10 year return -

Travere Therapeutics Inc Institutional Holdings

HHG PLC 11.49

FMR Inc 10.43

BlackRock Inc 8.78

Vanguard Group Inc 6.84

Macquarie Group Ltd 5.40

Perceptive Advisors LLC 4.11

Armistice Capital, LLC 4.08

State Street Corp 3.49

Strategic Advisers Fidelity US TtlStk 3.21

Adage Capital Partners Gp LLC 3.17

Vanguard Total Stock Mkt Idx Inv 3.06

State Street® SPDR® S&P® Biotech ETF 3.06

Renaissance Technologies Corp 2.44

Nomura Small Cap Core I 2.43

Rock Springs Capital Management LP 2.40

Geode Capital Management, LLC 2.32

iShares Russell 2000 ETF 2.18

Stephens Inv Mgmt Group LLC 1.87

Deutsche Bank AG 1.73

Emerald Advisers, LLC 1.73

Janus Henderson Global Life Sciences 1.56

Janus Henderson Global Life Sciences D 1.56

Eversept Partners, LP 1.54

Bank of America Corp 1.52

The Goldman Sachs Group Inc 1.38

Janus Henderson Glb Life Scn I2 USD 1.38

Stephens SMID Select Growth 1.34

Janus Global Life Science AUSD 1.34

Vanguard Explorer Inv 1.31

Two Sigma Investments LLC 1.25

Morgan Stanley - Brokerage Accounts 1.21

Janus Henderson Hrzn Biotec E2 USD 1.12

MEDICAL BioHealth EUR Acc 1.09

Vanguard Institutional Extnd Mkt Idx Tr 1.05

HBM Healthcare Investments AG Ord 1.01

Fidelity Blue Chip Growth 1.00

Fidelity Small Cap Growth 0.98

apo Medical Opportunities R 0.88

Fidelity Small Cap Index 0.88

Janus Henderson US SMID Cap Growth 0.83

Travere Therapeutics Inc Market Status

Strong Buy: 11

Buy: 2

Hold: 2

Sell: 0

Strong Sell: 0

Travere Therapeutics Inc Fundamentals

Market Cap 2626.12 M

PB Ratio 22.87

PE Ratio 0.0

Enterprise Value 2632.05 M

Total Assets 605.19 M

Volume 1069524

Travere Therapeutics Inc Company Financials

Annual Revenue FY25:490728000 490.7M, FY24:233175000 233.2M, FY23:232076000 232.1M, FY22:212018000 212.0M, FY21:227490000 227.5M

Annual Profit FY25:419646000 419.6M, FY24:233175000 233.2M, FY23:221150000 221.2M, FY22:204426000 204.4M, FY21:220706000 220.7M

Annual Net worth FY25:-50261000 -50.3M, FY24:-321545000 -321.5M, FY23:-87049000 -87.0M, FY22:-278482000 -278.5M, FY21:-180091000 -180.1M

Quarterly Revenue Q4/2025:129689000 129.7M, Q3/2025:164859000 164.9M, Q2/2025:114449000 114.4M, Q1/2025:81732000 81.7M, Q4/2024:74787000 74.8M

Quarterly Profit Q4/2025:108999000 109.0M, Q3/2025:163274000 163.3M, Q2/2025:112928000 112.9M, Q1/2025:77053000 77.1M, Q4/2024:72234000 72.2M

Quarterly Net worth Q4/2025:-21986000 -22.0M, Q3/2025:25706000 25.7M, Q2/2025:-12755000 -12.8M, Q1/2025:-41226000 -41.2M, Q4/2024:-60264000 -60.3M

About Travere Therapeutics Inc & investment objective

Company Information Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.

Organisation Biotechnology

Employees 497

Industry Biotechnology

CEO Dr. Eric M. Dube Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow